Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14299109 | 0.89 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL15080255 | 0.88 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL15080265 | 0.88 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL15080250 | 0.87 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL15080251 | 0.87 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL15080256 | 0.87 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL15080266 | 0.86 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL15080258 | 0.82 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL15080257 | 0.81 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 | |
| SCHEMBL15080262 | 0.80 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A4 4537/4885SLC6A2 3501/4885SLC6A3 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.